FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

KI	1169	AND	EXCHANGE	COMMISSION

OMB APP	'ROVAL
OMB Number:	3235-0287
Estimated average	burden

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Huang Jane				2. Issuer Name and Ticker or Trading Symbol Prelude Therapeutics Inc [PRLD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O PRELUDE THERAPEUTICS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 01/04/2025								Officer (give title Other (specify below) President, CMO				
(Street)	NGTON D		19805 (Zip)		4. 11	f Ame	endment,	Date o	of Original	Filed	(Month/D	ay/Year)	6. Lir	ie) Form	filed by One	o Filing (Check e Reporting Pe re than One Re	rson
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D				action	ction 2A. Deemed Execution Date,		Code (Instr. 5)			red (A) or	5. Amo Securi Benefi	ount of ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock 01/04				4/2025	/2025		Code	v	Amount 9,37:	(A) (D)	FIICE	Transa (Instr.	ction(s) 3 and 4)	D	(mou. 4)		
			01/04	1/2025		F		3,859	(2) D	\$1.0	_	8,857	D				
		Т							uired, D , option					y Owned			
Security or (Instr. 3) Pri	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Date, Transactio Code (Inst			n of		6. Date Exercisa Expiration Date (Month/Day/Year			7. Title ar Amount of Securities Underlyin Derivative (Instr. 3 a	of s ig e Security	8. Price of Derivative Security (Instr. 5)		Owners Form: Ily Direct (I or Indire (I) (Instr	Beneficia Ownersh ct (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares				

Explanation of Responses:

- 1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
- 2. Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
- 3. The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

Remarks:

/s/ Krishna Vaddi, Attorney-in-

01/07/2025

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.